Tokyo, March 26, 2018  - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “the Company”) announced that it completed acquisition of its own shares, which was resolved by its Board of Directors on January 31, 2018, pursuant to Article 156 which is applicable in accordance with Article 165, paragraph 3 of the Companies Act.

Particulars

1. Class of shares acquired:  Common stock of the Company
2. Total number of shares acquired:  39,577,500 shares
3. Aggregate amount of acquisition cost: 59,999,993,195 yen
4. Period of acquisition: From February 1, 2018 to March 23, 2018
5. Method of acquisition: Purchased on the Tokyo Stock Exchange

(Reference)
1. Details of the resolution at the meeting of the Board of Directors (announced on January 31, 2018)

- Class of shares to be acquired: Common stock of the Company
- Total number of shares to be acquired:  Up to 42 million shares
  (The percentage compared to the total number of shares outstanding: 2.08%)
- Aggregate amount of acquisition cost: Up to 60 billion yen
- Period of acquisition: From February 1, 2018 to March 23, 2018